Aerie Pharmaceuticals gets $88M upfront in licensing agreement with Santen - Triangle Business Journal
AERIE PHARMACEUTICALS, INC. 10K 2021
Aerie Pharmaceuticals Using ROCK Inhibitors to Change Glaucoma Management | Ophthalmology Innovation Source
Aerie Pharmaceuticals Inc - Important Information The information in this presentation does not contain all of the information that a potential investor should review before investing in Aerie shares. The descriptions of
Aerie Pharmaceuticals Announces Agreement to Acquire Avizorex Pharma to Advance Its Dry Eye Program | World Pharma Today
Santen Expands License Agreement with Aerie for Rhopressa and Rocklatan | Market Scope
Aerie Pharmaceuticals Receives Positive CHMP Opinion for Roclanda® in the European Union | Business Wire
Aerie Pharmaceuticals Receives European Commission Approval for Roclanda® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% | Business Wire
Articles about Aerie Pharmaceuticals, Inc. | page 5
Is Aerie Pharmaceuticals Ireland Ltd. late reporting EU clinical trials?
Aerie Pharmaceuticals Inc - For Investor Use Important Information The information in this presentation does not contain all of the information that a potential investor should review before investing in Aerie shares.
Form 8-K AERIE PHARMACEUTICALS For: Jan 12
Aerie Pharmaceuticals, Inc.
Glaucoma Physician - February 12, 2021
EX-99.1
Aerie launches Ph3 trial for Roclatan eye drug in Europe - Drug Delivery Business
Aerie Pharmaceuticals Announces First Participant Dosed in the Phase 3 Registrational COMET-2 Study of AR-15512 for the Treatment of Dry Eye Disease | Business Wire
Aerie Pharmaceuticals Inc - Disclaimer The information in this presentation regarding Aerie Pharmaceuticals, Inc. (the “Company” or “Aerie”) does not contain all of the information that a potential investor should review before
Aerie Pharmaceuticals Receives European Commission Approval for Roclanda® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% | Business Wire
Aerie Pharmaceuticals Inc - For Investor Use Important Information The information in this presentation does not contain all of the information that a potential investor should review before investing in Aerie shares.
Alcon Completes Acquisition of Aerie Pharmaceuticals - Eyewire+
Rhopressa enrolled in second Phase 3 registration trial
EX-99.1
Mitchell de Long on LinkedIn: Aerie Pharmaceuticals Appoints Raj Kannan as Chief Executive Officer |…
Aerie Pharmaceuticals Inc - Important Information The information in this presentation does not contain all of the information that a potential investor should review before investing in Aerie shares. The descriptions of
